A study of Cohen et al22 revealed a modest therapeutic benefit (12% response rate) of pembrolizumab in the patients with PD‐L1 positive (≥1% positive cancer or IC) SDC, and it is thought that a combination treatment with chemotherapy may improve the clinical response rates (NCT03360890). This evidence concerns the gene CD274 and cancer.